Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents

Journal of Applied Toxicology

Volumn 35, Issue 9, 2015, Pages 1030-1039

  Wiśniowska, Barbara ^a   Mendyk, Aleksander ^a   Szlek, Jakub ^a   Kołaczkowski, Michał ^b   Polak, Sebastian ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b CRACOW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

ANN; Cardiac ion channels; HERG; ICa; IKr; IKs; INa; QSAR model; Screening

Indexed keywords

DRUG; ION CHANNEL; POTASSIUM CHANNEL HERG;

ARTICLE; CALCIUM CURRENT; COMPUTER MODEL; IN VITRO STUDY; ION CURRENT; PHYSICAL CHEMISTRY; POTASSIUM CURRENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SODIUM CURRENT; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; HEART; HUMAN; METABOLISM;

ACTION POTENTIALS; ANIMALS; COMPUTER SIMULATION; HEART; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937974234     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3095     Document Type: Article

References (61)

1. Anderson-Sprecher R. 1994. Model Comparisons and R2. Am. Stat. 48: 113-117.
2. Aptula AO, Cronin MT. 2004. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ. Res. 15: 399-411.
3. Bolton E, Wang Y, Thiessen P, Bryant S. 2008. PubChem: Integrated Platform of Small Molecules and Biological Activities. In Chapter 12 Annual Reports in Computational Chemistry, Ralph AW, David SC (eds). American Chemical Society: Washington, DC, 4; 217-241.
4. Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, Funck-Brentano C. 2012. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob. Agents Chemother. 56: 3261-3270.
5. Cannon AJ. 2012. monmlp: Monotone multi-layer perceptron neural network.
6. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R. 2004. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J. Pharmacol. Sci. 95: 311-319.
7. Danielsson BR, Lansdell K, Patmore L, Tomson T. 2003. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res. 55: 147-157.
8. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. 2005. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 26: 590-597.
9. Drolet B, Zhang S, Deschenes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J. 1999. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol. 10: 1597-1604.
10. Du CY, El Harchi A, Zhang YH, Orchard CH, Hancox JC. 2011. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis. J. Cardiovasc. Electrophysiol. 22: 1163-1170.
11. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC. 2007. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem. Pharmacol. 74: 425-437.
12. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. 2002. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301: 427-434.
13. Ermondi G, Visentin S, Caron G. 2009. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. Eur. J. Med. Chem. 44: 1926-1932.
14. Ferrer-Villada T, Navarro-Polanco RA, Rodriguez-Menchaca AA, Benavides-Haro DE, Sanchez-Chapula JA. 2006. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline. Eur. J. Pharmacol. 531: 1-8.
15. Friemel A, Zunkler BJ. 2010. Interactions at human ether-a-go-go-related gene channels. Toxicol. Sci. 114: 346-355.
16. Guo L, Guthrie H. 2005. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods 52: 123-135.
17. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K. 2006. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods 54: 116-129.
18. Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL. 2010. Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev. Technol. 8: 727-742.
19. ICH. 2005. Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM074963.pdf [accessed September 2014].
20. Jeon SH, Jaekal J, Lee SH, Choi BH, Kim KS, Jeong HS, Han SY, Kim EJ. 2011. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum. Exp. Toxicol. 30: 1649-1656.
21. Jo SH, Hong HK, Jung SJ, Chong SH, Yun JH, Koh YS, Choe H. 2007. Maprotiline block of the human ether-a-go-go-related gene (HERG) K+ channel. Arch. Pharm. Res. 30: 453-460.
22. Jo SH, Hong HK, Chong SH, Won KH, Jung SJ, Choe H. 2008. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur. J. Pharmacol. 592: 19-25.
23. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. 2002. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J. Pharmacol. Exp. Ther. 303: 688-694.
24. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. 2006. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 316: 1098-1106.
25. Kim KS, Kim EJ. 2005. The phenothiazine drugs inhibit hERG potassium channels. Drug Chem. Toxicol. 28: 303-313.
26. Kireeva N, Kuznetsov SL, Bykov AA, Tsivadze AY. 2013. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models. SAR QSAR Environ. Res. 24: 103-117.
27. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. 2004. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods 50: 93-101.
28. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. 2002. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450: 37-41.
29. Legates DR, McCabe GJ Jr. 1999. Evaluating the Use of " Goodness-of-Fit" Measures in Hydrologic and Hydroclimatic Model Validation. Water Resour. Res. 35: 233-241.
30. Li Q, Jorgensen FS, Oprea T, Brunak S, Taboureau O. 2008. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol. Pharm. 5: 117-127.
31. Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA. 2006. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J. Cardiovasc. Pharmacol. 48: 199-206.
32. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. 2003. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 139: 887-898.
33. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC. 2010. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide. J. Pharmacol. Toxicol. Methods 61: 178-191.
34. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D. 2011. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91: 53-61.
35. Moorthy NS, Ramos MJ, Fernandes PA. 2014. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools. J. Enzyme Inhib. Med. Chem. 29: 317-324.
36. Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. 2007. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J. Psychopharmacol. 21: 735-741.
37. Paul AA, Witchel HJ, Hancox JC. 2002. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. 136: 717-729.
38. Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI. 2008. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol. Pharmacol. 74: 1443-1452.
39. Polak S. 2013. In vitro to human in vivo translation - pharmacokinetics and pharmacodynamics of quinidine. ALTEX 30: 309-318.
40. Polak S, Wisniowska B, Glinka A, Polak M. 2012. Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition. BMC Pharmacol. Toxicol. 13: 6. doi:10.1186/2050-6511-13-6.
41. Rampe D, Brown AM. 2013. A history of the role of the hERG channel in cardiac risk assessment. J. Pharmacol. Toxicol. Methods 68: 13-22.
42. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC. 2004. Lidoflazine is a high affinity blocker of the HERG K(+)channel. J. Mol. Cell. Cardiol. 36: 701-705.
43. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. 2014. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167: 292-300.
44. Seierstad M, Agrafiotis DK. 2006. A QSAR model of HERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug Des. 67: 284-296.
45. Shen MY, Su BH, Esposito EX, Hopfinger AJ, Tseng YJ. 2011. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Chem. Res. Toxicol. 24: 934-949.
46. Springer C, Sokolnicki KL. 2013. A fingerprint pair analysis of hERG inhibition data. Chem. Cent. J. 7: 167.
47. Steinbeck C, Han Y, Kuhn S, Horlacher O, Luttmann E, Willighagen E. 2003. The Chemistry Development Kit (CDK): an open-source Java library for Chemo- and Bioinformatics. J. Chem. Inf. Comput. Sci. 43: 493-500.
48. Steinbeck C, Hoppe C, Kuhn S, Floris M, Guha R, Willighagen EL. 2006. Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. Curr. Pharm. Des. 12: 2111-2120.
49. Stockbridge N, Morganroth J, Shah RR, Garnett C. 2013. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well-coordinated? Drug Saf. 36: 167-182.
50. Szlek J, Pacławski A, Lau R, Jachowicz R, Mendyk A. 2013. Heuristic modeling of macromolecule release from PLGA microspheres. Int. J. Nanomed. 8: 4601-4611.
51. Thai KM, Ecker GF. 2008. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg. Med. Chem. 16: 4107-4119.
52. Tie HH. 2002. Cellular mechanisms of QT prolongation and proarrhythmiainduced by non-antiarrhythmic drugs. Thesis, University of New South Wales, New South Wales, Australia.
53. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. 2004. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur. J. Pharmacol. 484: 41-48.
54. Wang S, Li Y, Wang J, Chen L, Zhang L, Yu H, Hou T. 2012. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. Mol. Pharm. 9: 996-1010.
55. Wang S, Li Y, Xu L, Li D, Hou T. 2013. Recent developments in computational prediction of HERG blockage. Curr. Top. Med. Chem. 13: 1317-1326.
56. Waring MJ, Johnstone C. 2007. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 17: 1759-1764.
57. Wisniowska B, Polak S. 2009. hERG in vitro interchange factors-development and verification. Toxicol. Mech. Methods 19: 278-284.
58. Wisniowska B, Mendyk A, Fijorek K, Polak S. 2014. Computer-based prediction of the drug proarrhythmic effect - problems, issues, known and suspected challenges. Europace 16: 724-735.
59. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, Wheelan P, McIntyre MS, Bergquist ML, MacKenzie KI, Becherer JD, Hashim MA. 2008. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154: 1446-1456.
60. Yap CW. 2011. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J. Comput. Chem. 32: 1466-1474.
61. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. 1999. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. 10: 836-843.